Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19

Eur J Clin Pharmacol. 2021 Mar;77(3):435-437. doi: 10.1007/s00228-020-03008-6. Epub 2020 Oct 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenosine Monophosphate / adverse effects
  • Adenosine Monophosphate / analogs & derivatives*
  • Adverse Drug Reaction Reporting Systems / standards*
  • Alanine / adverse effects
  • Alanine / analogs & derivatives*
  • Antiviral Agents / adverse effects*
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic / standards*
  • Humans
  • Quality Indicators, Health Care
  • Research Design / standards*
  • Risk Assessment

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine